Replies to post #72022 on Biotech Values

[genisi]

Following is a list of the top ten M&A deals in the pharma sector:

ACQUIROR              TARGET                  VALUE    COMPLETED 
  
                                          ($ billion) 
 ---------------------------------------------------------------- 
 Pfizer Inc            Warner-Lambert Co       88.77   19/06/2000 
 Glaxo Wellcome PLC    SmithKline Beecham PLC  78.77   27/12/2000 
 Sanofi-Synthelabo SA  Aventis SA              65.65   20/08/2004 
 Pfizer Inc            Pharmacia Corp          60.7    15/04/2003 
 Roche Holding AG      Genentech Inc           43.65    * 
 ZENECA Group PLC      Astra AB                31.77   06/04/1999 
 Rhone-Poulenc SA      Hoechst AG              28.35   15/12/1999 
 Sandoz AG             Ciba-Geigy AG           28.22   17/12/1996 
 Novartis AG           Alcon Inc               27.73   ** 
 Monsanto Co           Pharmacia & Upjohn Inc  26.77   31/03/2000

* Announced July 21, 2008.
** Announced April 7, 2008.

Source: Thomson Reuters;

[DewDiligence]

I'm trying to think of the last merger of two pharmas that worked out good?

Sandoz + Ciba-Geigy = NVS might be the last one that clearly added shareholder value, and that was 13 years ago.

[DewDiligence]

Everyone was hoping Pfizer would go after the Bio industry and stir up some commotion.

Actually, in terms of manufacturing capacity, WYE is one of the five largest biotech companies.